Description

BRAVECTO CHEWABLE 500 MG

Indications

BRAVECTO Chewable 500 mg is indicated for the treatment and prevention of flea infestations and for the treatment of tick infestations in dogs. It is effective against various species of ticks, including the Ixodes ricinus (castor bean tick), Rhipicephalus sanguineus (brown dog tick), and Dermacentor variabilis (American dog tick). BRAVECTO provides long-lasting protection, with a single dose offering up to 12 weeks of efficacy against fleas and ticks, making it a convenient option for pet owners.

Mechanism of Action

BRAVECTO contains the active ingredient fluralaner, which is a member of the isoxazoline class of compounds. Fluralaner acts by inhibiting the function of certain neurotransmitter receptors in the nervous system of insects and arachnids. Specifically, it blocks the GABA-gated chloride channels and the glutamate-gated chloride channels, leading to hyperexcitation of the nervous system, paralysis, and ultimately death of the parasites. This mechanism provides a rapid onset of action against fleas and ticks, contributing to its effectiveness in controlling infestations.

Pharmacological Properties

Fluralaner is rapidly absorbed following oral administration, with peak plasma concentrations typically occurring within 8 hours. The bioavailability of BRAVECTO is high, allowing for effective delivery of the active ingredient. The drug is extensively distributed throughout the body, including the skin and adipose tissue, where it can exert its effects on external parasites. The elimination half-life of fluralaner is approximately 12 days, which supports its extended duration of action. The metabolism of fluralaner occurs primarily in the liver, and it is excreted mainly in the feces.

Contraindications

BRAVECTO should not be administered to dogs that are hypersensitive to fluralaner or any of the excipients in the formulation. It is contraindicated in puppies younger than 6 months of age and in dogs weighing less than 2 kg. Additionally, BRAVECTO should not be used in animals with a history of seizures or other neurological disorders without prior veterinary consultation.

Side Effects

BRAVECTO is generally well-tolerated in dogs; however, some side effects may occur. Commonly reported side effects include vomiting, diarrhea, decreased appetite, lethargy, and increased thirst. In rare cases, neurological symptoms such as tremors, ataxia, or seizures may occur. If any severe adverse reactions are observed, it is crucial to contact a veterinarian immediately for further evaluation and management. Monitoring for side effects is recommended, especially during the initial administration of the product.

Dosage and Administration

The recommended dosage of BRAVECTO Chewable 500 mg is based on the weight of the dog. It is important to administer the correct dosage according to the weight range specified on the packaging. The chewable tablet should be given orally, with or without food. For optimal efficacy, it is recommended to administer BRAVECTO at intervals of 12 weeks. In cases of heavy flea or tick infestations, additional treatments may be necessary, and consultation with a veterinarian is advised.

Interactions

BRAVECTO is generally safe to use with other medications; however, caution should be exercised when administering it alongside other products that affect the central nervous system. The concurrent use of other isoxazolines or neurotoxic agents may increase the risk of adverse effects. It is essential to inform the veterinarian of all medications and supplements the dog is currently receiving to avoid potential drug interactions.

Precautions

Before administering BRAVECTO, a thorough veterinary examination is recommended, especially for dogs with a history of seizures or other neurological conditions. Pregnant or lactating dogs should only receive BRAVECTO if the benefits outweigh the risks, and it should be used with caution in dogs with pre-existing health conditions. Additionally, pet owners should ensure that the product is stored in a cool, dry place, away from direct sunlight and out of reach of children and pets.

Clinical Studies

Clinical studies have demonstrated the safety and efficacy of BRAVECTO in controlling flea and tick infestations in dogs. In a pivotal study, dogs treated with BRAVECTO showed a significant reduction in flea counts within 8 hours of administration, with sustained efficacy for 12 weeks. Another study highlighted the effectiveness of BRAVECTO against various tick species, with a rapid kill rate observed within 24 hours. These studies support the use of BRAVECTO as a reliable option for flea and tick control in canine patients.

Conclusion

BRAVECTO Chewable 500 mg is a highly effective and convenient option for the prevention and treatment of flea and tick infestations in dogs. With its long-lasting action, ease of administration, and favorable safety profile, BRAVECTO provides pet owners with a reliable solution to protect their pets from external parasites. Regular veterinary consultations and adherence to dosage recommendations are essential to ensure the optimal health and well-being of dogs receiving this treatment.